Key points
Continuous glucose monitoring (CGM) measures glucose every 1–5 minutes — up to 288 data points a day instead of a single fingerstick reading. Here is where that helps.
| Where it helps | How it helps | What human studies showed |
|---|---|---|
| Type 1 diabetes | a continuous picture of glucose; with an insulin pump — a hybrid closed-loop system: the algorithm adjusts basal insulin automatically from sensor data | FLASH-UK (NEJM 2022): in adults with type 1 diabetes, HbA1c was 0.5 percentage points lower and time in hypoglycemia 43 minutes a day shorter |
| Type 2 diabetes on insulin | shows how specific foods, physical activity and stress affect glucose | — |
| Pregnancy with type 1 diabetes | CGM from confirmation of pregnancy until delivery; a narrow target range of 3.5–7.8 mmol/L (63–140 mg/dL) | CONCEPTT RCT (n=325), CGM vs self-monitoring: large-for-gestational-age infants 53% vs 69%, neonatal hypoglycemia 15% vs 28%, the infant’s hospital stay one day shorter |
| Children and adolescents with type 1 diabetes | the same TIR target as adults; alarms for nocturnal hypoglycemia | T1D Exchange registry (n>22,000, children and adults): HbA1c lower in CGM users than in non-users |
| Impaired awareness of hypoglycemia in type 1 diabetes | real-time CGM (Dexcom G5 in HypoDE) | HypoDE RCT (n=149, 26 weeks): episodes with glucose at or below 3.0 mmol/L (54 mg/dL) fell from a mean of 10.8 to 3.5 per 28 days, 72% fewer |
| Prediabetes and metabolic health | a two-week course shows your own response to foods, hidden glucose spikes, and the effect of sleep, stress and exercise | — |
How it helps
How the sensor works
A glucometer gives a single value at the moment of the fingerstick — like assessing the weather from one snapshot a day. A CGM sensor is a miniature electrochemical biosensor inserted under the skin (typically on the back of the upper arm or the abdomen). A thin filament electrode (5–7 mm long, <0.4 mm in diameter) is coated with the enzyme glucose oxidase, which catalyzes the oxidation of glucose in interstitial fluid; the resulting current is proportional to glucose concentration.
Data is transmitted via Bluetooth or NFC to a smartphone or reader. CGM measures glucose in interstitial fluid, not in blood: there is a physiological lag of 5–15 minutes between the two (lag time). The technology has expanded well beyond type 1 diabetes: CGM is used in type 2 diabetes and prediabetes, and even healthy people use it to optimize metabolic health. The CGM market reached $8.2 billion in 2024 and is projected to reach $15 billion by 2028.
Time in range
An international consensus (Battelino et al., Diabetes Care, 2019) set targets for people with diabetes outside pregnancy (pregnancy targets are below). Optimal time in the 3.9–10.0 mmol/L (70–180 mg/dL) range is above 70%, i.e. more than 16 h 48 min a day.
| Metric | Target |
|---|---|
| Time in range 3.9–10.0 mmol/L (70–180 mg/dL) | >70% |
| Hypoglycemia: below 3.9 mmol/L (70 mg/dL) | <4% (<58 minutes) |
| Severe hypoglycemia: below 3.0 mmol/L (54 mg/dL) | <1% |
| Hyperglycemia: above 10.0 mmol/L (180 mg/dL) | <25% |
| Severe hyperglycemia: above 13.9 mmol/L (250 mg/dL) | <5% |
Each 5% increase in TIR is associated with an approximately 0.5% reduction in HbA1c (Beck et al., Annals of Internal Medicine, 2019). TIR >70% correlates with HbA1c <7%.
Glucose stability and the AGP report
Coefficient of variation (CV) is the key stability indicator: CV <36% means stable glycemia, above 36% unstable, with an increased risk of hypoglycemia. Monnier et al. (Diabetes Care, 2017) showed that glycemic variability is an independent risk factor for cardiovascular complications of diabetes.
Ambulatory Glucose Profile (AGP) is a standardized report that combines 14 days of data into one picture: median, 25th and 75th, and 5th and 95th percentiles.
Type 1 and type 2 diabetes
CGM + insulin pump = hybrid closed-loop system: the algorithm automatically adjusts basal insulin based on CGM data. AID systems (automated insulin delivery — Tandem Control-IQ, Medtronic 780G, Omnipod 5) suspend basal delivery when hypoglycemia is predicted and reduce its frequency by 30–50%. FLASH-UK results in type 1 diabetes are in “Key points” (PMID: 36198143).
In type 2 diabetes, CGM helps you see how specific foods, physical activity and stress affect glucose.
Prediabetes and metabolic health
A two-week CGM course lets you identify individual responses to foods, detect hidden glucose spikes (reactive hypoglycemia, nocturnal rises), and assess the effect of sleep, stress and physical activity, while visual feedback motivates changes in eating behavior.
Pregnancy
Pregnancy with type 1 diabetes carries a twofold risk of congenital anomalies, preeclampsia and fetal macrosomia. The multicenter CONCEPTT RCT compared CGM with standard self-monitoring (outcomes are in “Key points”); HbA1c in the CGM group was 0.19% lower by week 34 (PMID: 28923465).
Targets in pregnancy with T1D (Battelino consensus, 2019): a range of 3.5–7.8 mmol/L (63–140 mg/dL), time in it >70% (at least 16 h 48 min a day), above range <25%, below range <4%, including <1% below 3.0 mmol/L (54 mg/dL) (PMID: 31177185).
CGM is started once pregnancy is confirmed (4–6 weeks) and continued until delivery. After delivery, insulin requirements fall by 30–50% in the first 24–48 hours — CGM helps avoid postpartum hypoglycemia, especially during breastfeeding. In gestational diabetes, observational data show a benefit of CGM with insulin therapy. FreeStyle Libre 2/3 and Dexcom G6/G7 are approved for use in pregnancy (the FDA lifted the off-label status for Dexcom G7 in 2024).
Children and adolescents
In children and adolescents with T1D the target is >70% of time in the 3.9–10.0 mmol/L (70–180 mg/dL) range, as in adults; it is harder to reach because of pubertal hormonal fluctuations, physical activity and eating behavior. Data from the T1D Exchange registry are in “Key points” (PMID: 30657336).
Dexcom G7 is approved from age 2, FreeStyle Libre 3 from age 4 (officially from 14 in some countries; off-label use from age 4 is common). In children under 6 the sensor is placed on the buttocks, away from abdominal fat: in lean children subcutaneous tissue is thinner than 5 mm, which raises the risk of the sensor detaching. For adolescents, alarm thresholds are individualized for the first 2–4 weeks: low 3.9 mmol/L (70 mg/dL), high 13.9 mmol/L (250 mg/dL) instead of the standard 4.4 and 10.0 mmol/L (80 and 180 mg/dL).
When hypoglycemia goes unnoticed
Impaired awareness of hypoglycemia (IAH) develops in 20–25% of people with T1D with a diabetes duration over 10 years because of an impaired counterregulatory response of the sympathetic nervous system, and it raises the risk of severe hypoglycemia 6-fold. It is assessed with the Gold and Clarke scales (≥4 points — IAH present). In the multicenter HypoDE RCT in people with T1D and IAH, CGM (Dexcom G5) reduced episodes with glucose at or below 3.0 mmol/L (54 mg/dL) by 72% (p<0.0001) (PMID: 29459019).
Predictive low glucose alerts on Dexcom G7 and FreeStyle Libre 3 fire 20 minutes before a forecast drop below the threshold; the algorithm relies on the rate of change and the trend. Sensitivity is about 85%, specificity 75%. ADA 2024 Standards of Care place people with IAH in the category for whom CGM is mandatory (category A) and AID integration desirable (category B).
How to use it
1. Define your goal: diabetes management, metabolic optimization, ketosis monitoring
2. Choose a system: FreeStyle Libre 3 (best value), Dexcom G7 (best pump integration)
3. Set the period: at least 14 days for a complete picture
4. Keep a food diary: match meals with glycemic responses
5. Interpret with your doctor: share the AGP report with your endocrinologist
Available systems (2025–2026)
- FreeStyle Libre 3 (Abbott) — 21.2 mm, the smallest CGM in the world; 14 days; a reading every minute, continuous Bluetooth Low Energy transmission; MARD 7.9% (one of the best figures); factory calibration; customizable hypo- and hyperglycemia alerts; IP27 water resistance (submersion to 1 m for 30 minutes).
- Dexcom G7 — 28 mm (60% smaller than G6); 10 days + a 12-hour grace period; every 5 minutes, Bluetooth; MARD 8.2% (adults); no calibration required; integration with Omnipod 5 and Tandem Mobi pumps; trend arrows (↑↑, ↑, →, ↓, ↓↓) show the rate of change.
- Dexcom Stelo (2025) — the first CGM cleared by the FDA for people not on insulin (type 2 diabetes without insulin, prediabetes); 15 days; over the counter (OTC) in the US; a simplified interface without hypoglycemia alerts.
- SiBio KS1 — the world's first continuous ketone monitor: 14 days, measures beta-hydroxybutyrate (BHB) in interstitial fluid; ideal for monitoring ketosis (ketogenic diet, intermittent fasting), and combined with CGM gives a complete metabolic picture.
Accuracy and trend
Dexcom G7 with factory calibration delivers MARD 8.2% from activation (30-minute warm-up). The ISO 15197:2013 standard requires glucometers to have 95% of values within ±0.8 mmol/L (±15 mg/dL) at glucose ≤5.6 mmol/L (100 mg/dL) or within ±15% above 5.6 mmol/L (100 mg/dL); modern CGMs meet this standard, but not in all ranges (see “Who should see a doctor first”).
The lag between capillary and interstitial glucose is 5–10 minutes when glycemia is stable and 15–20 minutes during rapid changes (after meals, during exercise, during hypoglycemia). Pressure on the sensor during sleep can cause compression false lows.
Skin under the sensor
Contact dermatitis at the insertion site occurs in 5–18% of users: irritant in 65% of cases, allergic in 35%. The main allergen is isobornyl acrylate (IBOA), a component of the FreeStyle Libre adhesive (PMID: 28804907). Additional allergens are N,N-dimethylacrylamide and colophony.
- A barrier spray (Cavilon No-Sting, Marathon, SkinTac) before insertion reduces the rate of reactions by 40–60%.
- A hydrocolloid underlay (DuoDerm Extra Thin, Hydrocolloid) with a slit for the sensor isolates the skin from the adhesive.
- Class III topical corticosteroids (mometasone 0.1%, methylprednisolone aceponate 0.1%) — a short 5–7-day course; do not apply directly under the sensor (it impairs adhesion).
- Rotating insertion sites (forearm ↔ abdomen ↔ buttocks) every 8–14 days reduces local sensitization. Stopping CGM altogether is rarely required.
Who should see a doctor first
Choosing a CGM system and interpreting the data are done together with your doctor. In particular:
- When to see a doctor. If glucose is repeatedly below 3.0 mmol/L (54 mg/dL) or above 8.9 mmol/L (160 mg/dL), see a doctor (the author’s rule).
- Low readings and a mismatch with how you feel. During hypoglycemia CGM may show a value higher than the real one — confirmation with a glucometer is mandatory at values <3.9 mmol/L (70 mg/dL) and when readings contradict symptoms. Accuracy is lower at glucose <3.9 mmol/L (70 mg/dL) and >16.7 mmol/L (300 mg/dL).
- The first hours after insertion. Readings are less accurate in the first 24 hours (stabilization period); do not adjust insulin based on absolute values in the first 12 hours, follow the trend. When calculating an insulin bolus, the trend (up/down arrow) is taken into account, and during a rapid rise the CGM value + 20–30% correction is used.
- What distorts readings. Paracetamol >1 g (Dexcom G6 and older — falsely high values; G7 has an improved electrode with reduced sensitivity), ascorbic acid >500 mg (FreeStyle Libre — falsely high), dehydration (reduced interstitial perfusion — falsely low). Hemodialysis and marked swings in hematocrit also affect accuracy; in stage 5 CKD, CGM is used with caution.
- Pregnancy. With third-trimester edema accuracy may decrease — MARD rises from 8% to 10–12%; if readings seem to diverge from symptoms, confirmation with a glucometer is recommended.
- Children. Dexcom Stelo is not yet indicated for children. In children with obesity and prediabetes there is no routine indication for CGM: prediabetes and T2D in children are diagnosed by HbA1c, OGTT and fasting glucose.
- Skin. Erythema, itching and vesicles over an area larger than the patch outline appearing after 24–72 hours are signs of allergy (delayed type IV hypersensitivity): patch testing by a dermatologist and switching systems (Dexcom uses a different adhesive formula than Abbott). Mechanical irritation follows the outline exactly, without itching; tenderness and a pustule point to infection (folliculitis, S. aureus); cholinergic urticaria is also ruled out.
Bottom line
CGM turns a single reading into a continuous picture: you see time in range, glucose stability and your response to food, sleep and exercise. In human studies, with CGM HbA1c fell and hypoglycemia became less frequent, and in pregnant women with type 1 diabetes large-for-gestational-age infants and neonatal hypoglycemia were less common. A complete picture needs at least 14 days, and the AGP report is worth reviewing with an endocrinologist.
Do I need CGM for type 2 diabetes without insulin?
Even a short course (2–4 weeks) provides valuable insights: you see how specific foods, physical activity and stress affect glucose, and visual feedback motivates behavior change. Dexcom Stelo was cleared by the FDA specifically for this group.
Does CGM replace a glucometer?
For most decisions, yes. However, when accuracy is in doubt (pressure on the sensor during sleep, rapid glucose change), a confirmatory fingerstick is recommended, and at values below 3.9 mmol/L (70 mg/dL) that contradict symptoms, glucometer confirmation is mandatory.
Can a healthy person use CGM?
Yes, to optimize metabolic health: CGM reveals individual responses to foods and hidden insulin resistance. A 2–4 week course is informative.
Is CGM insertion painful?
Most users describe insertion as a light click. The filament electrode is so thin that it is usually not felt after insertion.
What is the target glucose range on CGM?
According to the international consensus (Battelino, 2019), for people with diabetes outside pregnancy the target is more than 70% of the day in the 3.9–10.0 mmol/L (70–180 mg/dL) range, less than 4% below 3.9 mmol/L (70 mg/dL), less than 1% below 3.0 mmol/L (54 mg/dL), less than 25% above 10.0 mmol/L (180 mg/dL) and less than 5% above 13.9 mmol/L (250 mg/dL). The target is the same for children and adolescents with type 1 diabetes. In pregnant women with type 1 diabetes the range is narrower — 3.5–7.8 mmol/L (63–140 mg/dL), with the target also above 70% of the time.
What should I do if the skin under the sensor turns red and itchy?
A barrier spray before insertion reduces the rate of reactions by 40–60%; a hydrocolloid underlay with a slit for the sensor and changing insertion sites every 8–14 days also help. If redness, itching or blisters spread beyond the patch outline after 24–72 hours, these are signs of an adhesive allergy: patch testing by a dermatologist and possibly switching systems are needed. Tenderness and a pustule point to infection.
Source: CGM Sensors: How Real-Time Glucose Monitoring Is Changing Diabetes Treatment — universum.earth. md_pereligyn — Перелыгин Владимир Игоревич.
